Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

AbbVie, Regenxbio team up to develop gene therapy for eye diseases

by Megha Satyanarayana
September 18, 2021 | A version of this story appeared in Volume 99, Issue 34

 

AbbVie and Regenxbio are partnering to develop RGX-314, a gene therapy in clinical trials for eye diseases. AbbVie will pay Regenxbio $370 million up front and up to $1.38 billion more. RGX-314 is intended to be a one-time therapy for wet age-related macular degeneration. The treatment uses a viral vector to carry the genetic information for part of a monoclonal antibody that blocks a growth factor tied to the formation of leaky blood vessels.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.